Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PLEC | Q15149 | 1/20 | 0.31 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025900 | 1.00 | PDE5A (0.39) | PDE5ATSHRHSP90AA1HSP90AB1MAPT | |
| SCHEMBL10025901 | 1.00 | PDE5A (0.39) | PDE5ATSHRHSP90AA1HSP90AB1MAPT | |
| SCHEMBL10025911 | 0.93 | PDE5A (0.36) | PDE5ATSHR | |
| SCHEMBL13822083 | 0.90 | TSHR (0.33) | TSHRSLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL10025899 | 0.90 | TSHR (0.34) | TSHRFFAR2POLB | |
| SCHEMBL10025898 | 0.90 | TSHR (0.34) | TSHRFFAR2POLB | |
| SCHEMBL10025912 | 0.82 | FFAR2 (0.33) | TSHRFFAR2POLB | |
| SCHEMBL10025902 | 0.82 | FFAR2 (0.33) | TSHRFFAR2POLB | |
| SCHEMBL10025903 | 0.82 | FFAR2 (0.33) | TSHRFFAR2POLB | |
| SCHEMBL10025893 | 0.77 | P2RX7 (0.38) | TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124616-B2 | Bicyclic PPAT inhibitors as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-28 | — | — | US | disclosed |
| US-8124616-B2 | Bicyclic PPAT inhibitors as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2012-02-28 | — | — | US | disclosed |
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | MAXTHERA INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203730-A1 | BICYCLIC PPAT INHIBITORS AS ANTIBACTERIAL AGENTS | APRT, PPA1, GNPAT | PDE5A 1280/4885TSHR 4249/4885HSP90AA1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.